Amedisys (AMED) 10-Q 4 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	AMED
Entity Registrant Name	AMEDISYS INC
Entity Central Index Key	896,262
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		33,418,579
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 7,824	$ 27,502
Patient accounts receivable, net of allowance for doubtful accounts of $16,751, and $16,526	153,860	125,010
Prepaid expenses	9,086	8,110
Other current assets	5,959	14,641
Total current assets	176,729	175,263
Property and equipment, net of accumulated depreciation of $143,277 and $141,793	43,963	42,695
Goodwill	285,124	261,663
Intangible assets, net of accumulated amortization of $25,885 and $25,386	43,548	44,047
Deferred income taxes	121,367	125,245
Other assets, net	34,914	32,802
Total assets	705,645	681,715
Current liabilities:
Accounts payable	33,627	25,682
Payroll and employee benefits	82,837	72,546
Accrued expenses	63,903	71,965
Current portion of long-term obligations	20,000	5,000
Total current liabilities	200,367	175,193
Long-term obligations, less current portion	90,565	91,630
Other long-term obligations	3,934	4,456
Total liabilities	294,866	271,279
Commitments and Contingencies - Note 5	0	0
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding	0	0
Common Stock, $0.001 par value, 60,000,000 shares authorized; 34,849,466, and 34,786,966 shares issued; and 33,340,512 and 33,607,282 shares outstanding	35	35
Additional paid-in capital	510,881	504,290
Treasury Stock at cost 1,508,954 and 1,179,684 shares of common stock	(39,529)	(26,966)
Accumulated other comprehensive income	15	15
Retained earnings	(61,593)	(67,806)
Total Amedisys, Inc. stockholders' equity	409,809	409,568
Noncontrolling interests	970	868
Total equity	410,779	410,436
Total liabilities and equity	$ 705,645	$ 681,715

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Patient accounts receivable, allowance for doubtful accounts	$ 16,751	$ 16,526
Property and equipment, accumulated depreciation	143,277	141,793
Intangible assets, accumulated amortization	$ 25,885	$ 25,386
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	60,000,000	60,000,000
Common Stock, shares issued	34,849,466	34,786,966
Common Stock, shares outstanding	33,340,512	33,607,282
Treasury Stock at cost, shares	1,508,954	1,179,684

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net service revenue	$ 348,817	$ 301,572
Cost of service, excluding depreciation and amortization	201,837	170,961
General and administrative expenses:
Salaries and benefits	76,717	68,555
Non-cash compensation	4,070	2,384
Other	46,717	33,070
Provision for doubtful accounts	3,940	2,976
Depreciation and amortization	4,473	6,537
Asset impairment charge	0	75,193
Operating expenses	337,754	359,676
Operating income (loss)	11,063	(58,104)
Other (expense) income:
Interest income	22	22
Interest expense	(1,112)	(2,426)
Equity in (loss) earnings from equity method investments	(5)	1,951
Miscellaneous, net	735	2,134
Total other (expense) income, net	(360)	1,681
Income (loss) before income taxes	10,703	(56,423)
Income tax (expense) benefit	(4,388)	21,591
Net income (loss)	6,315	(34,832)
Net income attributable to noncontrolling interests	(102)	(177)
Net income (loss) attributable to Amedisys, Inc.	$ 6,213	$ (35,009)
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$ 0.19	$ (1.07)
Weighted average shares outstanding	32,920	32,739
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$ 0.19	$ (1.07)
Weighted average shares outstanding	33,508	32,739
Income Amounts Attributable To Reporting Entity Disclosures [Abstract]
Net income (loss) attributable to Amedisys, Inc.	$ 6,213	$ (35,009)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ 6,315	$ (34,832)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,473	6,537
Provision for doubtful accounts	3,940	2,976
Non-cash compensation	4,070	2,384
401(k) employer match	1,737	1,813
Loss on disposal of property and equipment	360	196
Deferred income taxes	4,038	(22,165)
Equity in loss (earnings) of equity method investments	5	(1,951)
Amortization of deferred debt issuance costs/debt discount	185	276
Return on equity investment	362	645
Asset impairment charge	0	75,193
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(27,689)	(14,302)
Other current assets	7,845	(3,677)
Other assets	(2,775)	(1,014)
Accounts payable	9,098	8,156
Accrued expenses	801	(5,681)
Other long-term obligations	(521)	(71)
Net cash provided by operating activities	12,244	14,483
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets	230	64
Purchases of deferred compensation plan assets	0	(19)
Purchases of property and equipment	(6,702)	(2,113)
Acquisitions of businesses, net of cash acquired	(27,682)	0
Net cash used in investing activities	(34,154)	(2,068)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options and warrants	0	181
Proceeds from issuance of stock to employee stock purchase plan	638	504
Tax benefit from stock options exercised and restricted stock vesting	159	0
Proceeds from revolving line of credit	40,500	40,800
Repayments of revolving line of credit	(25,500)	(55,800)
Principal payments of long-term obligations	(1,250)	(3,000)
Purchase of company stock	(12,315)	0
Net cash provided by (used in) financing activities	2,232	(17,315)
Net decrease in cash and cash equivalents	(19,678)	(4,900)
Cash and cash equivalents at beginning of period	27,502	8,032
Cash and cash equivalents at end of period	7,824	3,132
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	648	1,827
Cash paid for income taxes, net of refunds received	$ (7)	$ (89)

NATURE OF OPERATIONS, CONSOLIDA

NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS	1 . NATURE OF OPERATIONS , CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS Amedisys , Inc., a Delaware corporation, and its consolidated subsidiaries (“ Amedisys ,” “we,” “us,” or “our”) are a multi-state provider of home health and hospice services with approximately 79% and 81% of our revenue derived from Medicare for the three - month period s ended March 31, 2016 and 2015 , respectively . As of March 31, 2016 , we owned and operated 329 Medicare-certified home health care centers , 79 Medicare-certified hospice care centers and nine personal - care care centers in 34 states within the United St ates and the District of Columbia . Basis of Presentation In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated finan cial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 , as filed with the Securities and Exchange Commission (“SEC”) on March 10, 2016 (the “Form 10-K”), which includes information and disclosures not included herein. Use of Estimates Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Reclassifications and Comparability Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period' s presentation. In compliance with Accounting Standards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs , we have reclassified 2015 amounts related to unamortized debt issuance costs from other assets, net to long-term obligations, less current portio n. Principles of Consolidation These unaudited condensed c onsolidated financial statements include the accounts of Amedisys , Inc. , and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below . Equity Investments We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50 %. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50 % or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $ 25.4 million as of March 31 , 201 6 and $ 25.7 m illion as of December 31, 201 5 . We account for investments in entities in which we have less than a 20 % ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee .

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2 . Summary of Significant Accounting Policies Revenue Recognition We earn net service revenue through our home health and hospice care center s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60 -day episode of care as episodic-based revenue. When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. Home Health Revenue Recognition Medicare Revenue Net service revenue is recorded under the Medicare prospective payment system (“PPS”) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (“LUPA”) if the number of visits was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g) changes in the base episode payments established by the Medicare Program; (h) adjustments to the base episode payments for case mix and geographic wages; and (i) recoveries of overpayments. In addition, we make adjustments to Medicare revenue if we find that we are unable to produce appropriate documentation of a face to face encounter between the patient and physician. We make adjustments to Medicare revenue to reflect differences between estimated and actual payment amounts, our discovered inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99 % on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60 -day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of March 31, 2016 and 2015 , the difference between the cash received from Medicare for a request for anticipated payment (“RAP”) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa tient accounts receivable in our condensed consolidated balance sheets for such periods. Non-Medicare Revenue Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Non-episodic b ased Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. Hospice Revenue Recognition Hospice Medicare Revenue Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continu ous home care and respite care. Routine care accounts for 98 % of our total net Medic are hospice service revenue for each of the three - month period s ended March 31, 2016 , and 2015 . We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if we estimate a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated cap liability by March 31 st of the following year. As of March 31, 2016, w e have settled our Medicare hospice reimbursements for all fiscal years through October 31, 20 12 . As of March 31, 201 6 and December 31, 201 5 , we have recorded $ 1.3 million and $ 1.4 million , respectively , for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through October 31, 201 6 . Hospice Non-Medicare Revenue We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv able. Patient Accounts Receivable Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March 31, 2016 t here is one single payor, other than Medicare, that accounts for more than 10 % of our total outstanding patient receivables (approximately 11.6 %). T hus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 36 5 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the credit risk associated with our Medicare accounts , which represent 60 % and 64 % of our net patient accounts receivable at March 31, 201 6 and December 31, 2015 , respectively, is limited due to our historical collection rate of over 99 % from Medicare and the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above . During the three - month periods ended March 31, 2016 and 2015 , we recorded $ 1. 7 million and $ 1. 5 million, respectively , in estimated revenue adjustments to Medicare revenue. We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. Medicare Home Health For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60 % of our estimated payment for the initial episode at the start of care or 50 % of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (“final billed”). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted. Medicare Hospice For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient . Non-Medicare Home Health and Hospice For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. We estimate an allowance for doubtful accounts based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectability based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk . Property and Equipment Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed c om puter software for our own use . Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses. As of December 31, 2014, we had $ 75.8 million of internally developed software costs related to the development of AMS3 H ome H ealth and Hospice . Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three - month period ended March 31, 2015, we made the decision to discontinue AMS3 and recorded a non-cash asset impairment charge of $75.2 million to write-off the software costs incurred related to the development of AMS3 Home Health and Hospice . The following table summarizes the balances related to our property and equipment for the periods indicated (amounts in millions): March 31, 2016 December 31, 2015 Building and leasehold improvements 5.1 2.3 Equipment and furniture 89.2 89.6 Computer software 93.0 92.6 187.3 184.5 Less: accumulated depreciation (143.3) (141.8) $ 44.0 $ 42.7 Fair Value of Financial Instruments The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows: Level 1 – Quoted prices in active markets for identical assets and liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable , payroll and employee benefits and accrued expenses , we estimate the carrying amounts' approximate fair value. As of March 31, 2016, the carrying amount of our long-term debt is subject to a variable rate of interest based on current market rates, and as such, the carrying value approximates fair value . Weighted-Average Shares Outstanding Net income ( loss ) per share attributable to Amedisys , Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calc ulate our basic and diluted net income (l oss ) attributable to Amedisys , Inc. common stock holders (amounts in thousands): For the Three-Month Periods Ended March 31 2016 2015 Weighted average number of shares outstanding - basic 32,920 32,739 Effect of dilutive securities: Stock options 82 0 Non-vested stock and stock units 506 0 Weighted average number of shares outstanding - diluted 33,508 32,739 Anti-dilutive securities 319 875 Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) , which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , to defer the effective date of the standard from January 1, 2017 to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 and ASU 2015-14 will have on its consolidated financial statements and related disclosures, its transition method and the effect of the standard on its ongoing financial reporting. In April 2015, t he FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods beginning on or after December 15, 2015 . We adopted this ASU during three-month period ended March 31, 201 6 , and applied the change retrospectively for prior period balances of unamortized debt issuance costs, resulting in a $3. 4 million reduction in other assets, net and long-term obligations, less current portion, on our condensed consolidated balance sheet as of December 31, 2015. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which will require lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guidance for all periods presented. The Company is evaluating the effect that ASU 2016-02 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting . In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , which will simplify the accounting for share-based payment award transactions , including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the effect that ASU 2016-09 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting .

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
ACQUISITIONS	3 . ACQUISITIONS We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy . We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed. On March 1, 2016, we acquired Associated Home Care for a total purchase price of $ 2 7.7 million, net of cash acquired (subject to certain adjustments), of which $ 0.5 million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Associated Home Care own s and operate s 9 care centers servicing the state of Massachusetts. Based on our preliminary purchase price allocation, i n connection with the acquisition, we recorded goodwill ($ 23.5 million) and other assets and liabilities, net ($ 4. 2 million). The purchase price allocation is pending finalization of the report from our outside appraisal firm and the impact on goodwill and other intangibles .

LONG-TERM OBLIGATIONS

LONG-TERM OBLIGATIONS	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
LONG-TERM OBLIGATIONS	4. LONG-TERM OBLIGATIONS Long-term debt consisted of the following for the periods indicated (amounts in millions): March 31, 2016 December 31, 2015 $100.0 million Term Loan; principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (2.43% at March 31, 2016); due August 28, 2020 $ 98.8 $ 100.0 $200.0 million Revolving Credit Facility; interest only payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (2.44% at March 31, 2016); due August 28, 2020 15.0 0.0 Deferred debt issuance costs (3.2) (3.4) 110.6 96.6 Current portion of long-term obligations (20.0) (5.0) Total $ 90.6 $ 91.6 Our weighted average interest rate for our $100.0 million Term Loan, under our Credit Agreement, was 2. 4 % for the three-month period ended March 31, 2016. Our weighted average interest rate for our $200.0 million Revolving Credit Facility was 2.7 % for the three-month period ended March 31, 2016. As of March 31, 2016, our consolidated leverage ratio was 1. 0 , our consolidated fixed charge coverage ratio was 3. 8 and we are in compliance with our Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments. As of March 31, 2016, our availability under our $200.0 million Revolving Credit Facility was $ 160.3 million as we had $ 24.7 million outstanding letters of credit.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	5 . COMMITMENTS AND CONTINGENCIES Legal Proceedings - Ongoing We are involved in the following legal actions: Securities Class Action Lawsuits On June 10, 2010, a putative securities class action complaint was filed in the United States District Court for the Middle District of Louisiana (the “District Court”) against the Company and certain of our current and former senior executives. Additional putative securities class actions were filed in the District Court on July 14, July 16, and July 28, 2010. On January 18, 2011, the Co-Lead Plaintiffs filed an amended, consolidated class action complaint (the “Securities Complaint”) which supersedes the earlier-filed securities class action complaints. The Securities Complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The Securities Complaint seeks a determination that the action may be maintained as a class action on behalf of all persons who purchased the Company's securities between August 2, 2005 and September 28, 2010 and an unspecified amount of damages. All defendants moved to dismiss the Securities Complaint. On June 28, 2012, the District Court granted the defendants' motion to dismiss the Securities Complaint. On July 26, 2012, the Co-Lead Plaintiffs filed a motion for reconsideration, which the District Court denied on April 9, 2013. On May 3, 2013, the Co-Lead Plaintiffs appealed the dismissal of the Securities Complaint to the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”). On October 2, 2014, a three-judge panel of the Fifth Circuit issued a decision reversing the District Court's dismissal of the Securities Complaint. On October 16, 2014, all defendants filed a petition with the Fifth Circuit to review the three-judge panel's decision en banc , or as a whole court. On December 29, 2014, the Fifth Circuit denied the defendants' motion for en banc review of the Fifth Circuit panel's decision reversing the District Court's dismissal of the Securities Complaint. The case then returned to the District Court for further proceedings. On March 30, 2015, the defendants filed a Petition for Writ of Certiorari (the “Petition”) with the United States Supreme Court asking the Supreme Court to consider whether the Fifth Circuit erred in reversing the District Court's dismissal of the Securities Complaint. The Supreme Court denied the Petition on June 29, 2015, which did not affect the ongoing proceedings before the District Court, including the District Court's consideration of a motion filed on April 3, 2015, by the Co-Lead Plaintiffs for leave to amend the Securities Complaint, which motion was granted by the District Court. On December 15, 2015, the defendants filed a motion to dismiss the Co-Lead Plaintiffs' First Amended Consolidated Complaint. All discovery in the case is currently stayed pursuant to federal law. The parties have agreed to explore the possibility of a mediated settlement of this matter, and a mediation is scheduled to occur on June 21, 2016. No assurances can be given about the timing or outcome of this matter . We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities litigation described above. The Company intends to continue to vigorously defend itself in the securities litigation matter but, if decided adverse to the Company, its impact could be material. No assurances can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate. Wage and Hour Litigation On September 13, 2012, a putative collective and class action complaint was filed in the United States District Court for the Northern District of Illinois against us in which a former employee alleges wage and hour law violations. The former employee claims she was paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in her misclassification as an exempt employee, thereby denying her overtime. The plaintiff alleges violations of federal and state law and seeks damages under the Federal Fair Labor Standards Act (“FLSA”) and the Illinois Minimum Wage Law. Plaintiff seeks class certification of similar employees who were or are employed in Illinois and seeks attorneys' fees, back wages and liquidated damages going back three years under the FLSA and three years under the Illinois statute. On May 28, 2013, the Court granted the Company's motion to stay the case pending resolution of class certification issues and dispositive motions in the earlier-filed Connecticut case referenced below . On December 23, 2015 , the parties agreed to explore the possibility of a mediated settlement of the Illinois case, and a mediation occur red on April 18, 2016 . The parties agreed to settle the case for $0.8 million, subject to court approval, which we have accrued as of March 31, 2016. Frontier Litigation On April 2, 2015, Frontier Home Health and Hospice, L.L.C. (“Frontier”) filed a complaint against us in the United States District Court for the District of Connecticut alleging breach of contract, negligent misrepresentation and unfair and deceptive trade practices under Conn. Gen. Stat. §42-110b. Frontier acquired our interest in five home health and four hospice care centers in Wyoming and Idaho in April 2014. The complaint alleges that certain of the hospice patients on service at the time of the acquisition did not meet Medicare eligibility requirements and that we breached certain of the representations and warranties under the purchase agreement and therefore, the businesses were worth less than the purchase price. Under the complaint, Frontier seeks declaratory judgment from the District Court that, under the terms of the purchase agreement with Frontier, we are obligated to determine the amount of the alleged Medicare overpayments and reimburse the government for the same in a timely manner, as well as unspecified compensatory and punitive damages, attorneys' fees and pre- and post-judgment interest . We are unable to assess the probable outcome arising from the Frontier litigation described above. The Company has engaged an independent auditing firm to perform a clinical audit of the hospice locations in question and intends to defend itself in the Frontier litigation matter. No assurances can be given as to the timing or outcome of the audit, the Frontier litigation matter described above or the impact of any of the audit or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate. In accordance with our corporate integrity agreement (“CIA”) with the Office of Inspector General-HHS (“OIG”) as discussed below under “Other Investigative Matters – Corporate Integrity Agreement”, we have notified the OIG of this matter . Subpoena Duces Tecum Issued by the U.S. Department of Justice On May 21, 2015, we received a Subpoena Duces Tecum (“Subpoena”) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through the present. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. No assurance can be given as to the timing or outcome of this investigation. Civil Investigative Demand Issued by the U.S. Department of Justice On November 3, 2015, we received a civil investigative demand (“CID”) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. No assurance can be given as to the timing or outcome of this investigation. In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows. Legal Proceedings – Settled Wage and Hour Litigation On July 25, 2012, a putative collective and class action complaint was filed in the United States District Court for the District of Connecticut against us in which three former employees allege wage and hour law violations. The former employees claim that they were not paid overtime for all hours worked over 40 hours in violation of the FLSA, as well as the Pennsylvania Minimum Wage Act. More specifically, they allege they were paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in their misclassification as exempt employees, thereby denying them overtime pay. Moreover, in response to a Company motion arguing that plaintiffs' complaint was deficient in that it was ambiguous and failed to provide fair notice of the claims asserted and plaintiffs' opposition thereto, the Court, on April 8, 2013, held that the complaint adequately raises general allegations that the plaintiffs were not paid overtime for all hours worked in a week over 40, which may include claims for unpaid overtime under other theories of liability, such as alleged off-the-clock work, in addition to plaintiffs' more clearly stated allegations based on misclassification. On behalf of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek attorneys' fees, back wages and liquidated damages going back three years under the FLSA and three years under the Pennsylvania statute. On October 8, 2013, the Court granted plaintiffs' motion for equitable tolling requesting that the statute of limitations for claims under the FLSA for plaintiffs who opt-in to the lawsuit be tolled from September 24, 2012, the date upon which plaintiffs filed their original motion for conditional certification, until 90 days after any notice of this lawsuit is issued following conditional certification. Following a motion for reconsideration filed by the Company, on December 3, 2013, the Court modified this order, holding that putative class members' FLSA claims are tolled from October 29, 2012 through the date of the Court's order on plaintiffs' motion for conditional certification. On January 13, 2014, the Court granted plaintiffs' July 10, 2013 motion for conditional certification of their FLSA claims and authorized issuance of notice to putative class members to provide them an opportunity to opt in to the action. On April 17, 2014, that notice was mailed to putative class members. The period within which putative class members were permitted to opt into the action expired on July 16, 2014. On September 10, 2014, the plaintiffs in the Connecticut case filed a motion for leave to amend their complaint to add a new claim under the Kentucky Wage and Hour Act (“KWHA”) alleging that the Company did not pay certain home health clinicians working in the Commonwealth of Kentucky all of the overtime wages they were owed, either because the Company misclassified them as exempt from overtime or, while treating them as overtime eligible, did not properly pay them overtime for all hours worked over 40 in a week. On behalf of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek attorneys' fees, back wages and liquidated damages going back five years before the filing of their original complaint under the KWHA. On October 1, 2014, the Company filed an opposition to the plaintiffs' motion to amend. On October 15, 2014, plaintiffs filed a reply brief in support of their motion. On December 12, 2014, the Court granted the plaintiffs' motion to amend the complaint to add the claims under the KWHA. The Company and the plaintiffs agreed to explore the possibility of a mediated settlement of the Connecticut case, and on February 23, 2015 filed a joint motion to stay proceedings for six months to pursue that process, which was granted by the Court on February 24, 2015 . On June 10, 2015, the Company and plaintiffs participated in a mediation whereby they agreed to fully resolve all of plaintiffs' claims in the lawsuit for $8.0 million, subject to approval by the Court. The settlement agreement will be submitted to the Court for preliminary approval and plaintiffs will request certification of Pennsylvania and Kentucky classes for the sole purpose of this proposed settlement. If the Court grants preliminary approval, notice will be issued to members of the settlement classes to provide them with an opportunity to object to the settlement and, in the case of members of the Pennsylvania and Kentucky classes, opt out of the settlement. Following this notice period, the Court will hold a final fairness hearing for the purpose of considering objections and deciding whether to grant final approval of the settlement. As of September 30, 2015, we had an accrual of $8.0 million for this matter. On January 29, 2016, the Court approved the final settlement of this case. The settlement became effective on February 26, 2016. As a result of the final amount calculated by the settlement administrator based on claims timely submitted, we reduced our accrual to $5.3 million as of December 31, 2015 ; this amount was paid during the three-month period ended March 31, 201 6 . Other Investigative Matters Corporate Integrity Agreement On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (“CIA”) with the Office of Inspector General-HHS (“OIG”). The CIA formalizes various aspects of our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The corporate integrity agreement has a term of five years. During the course of our compliance with the CIA we have identified several such reportable events and have notified the OIG as required. The final resolution of these matters is still pending. As of March 31 , 201 6 , we have an accrual in the amount of $4.7 million to cover all repayments of extrapolated overpayments, damages and penalties that we believe could be assessed. Computer Inventory and Data Security Reporting On March 1 and March 2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an extensive risk management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at issue were originally assigned to Company clinicians and other team members who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information may be involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (“OCR”) is reviewing our compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory authorities. In accordance with our CIA, we have notified the OIG of this matter. Third Party Audits From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in whic h third party firms engaged by the Centers for Medicare and Medicaid Services (“CMS”) conduct extensive review of claims data to identify potential improper payments under the Medicare program. In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare Program Safeguard Contractor (“PSC”) a request for records regarding 137 claims submitted by the subsidiary paid from January 2, 2008 through November 10, 2009 (the “Claim Period”) to determine whether the underlying services met pertinent Medicare payment requirements. Based on the PSC's findings for 114 of the claims, which were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim Period, on March 9, 2011, the Medicare Administrative Contractor (“MAC”) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately $5.6 million. We dispute these findings, and our Dayton subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. A consolidated administrative law judge (“ALJ”) hearing was held in late March 2013. In January 2014, the ALJ found fully in favor of our Dayton subsidiary on 74 appeals and partially in favor of our Dayton subsidiary on eight appeals. Taking into account the ALJ's decision, certain determinations that our Dayton subsidiary decided not to appeal as well as certain determinations made by the MAC, of the 114 claims that were originally extrapolated by the MAC, 76 claims have now been decided in favor of our Dayton subsidiary in full, 10 claims have been decided in favor of our Dayton subsidiary in part, and 28 claims have been decided against or not appealed by our Dayton subsidiary. The ALJ has ordered the MAC to recalculate the extrapolation amount based on the ALJ's decision. The Medicare Appeals Council can decide on its own motion to review the ALJ's decisions. As of March 31, 2016 , we have recorded no liability with respect to the pending appeals as we do not believe that an estimate of a reasonably possible loss or range of loss can be made at this time. In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor (“ZPIC”) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the “Review Period”) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations. Based on the ZPIC's findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the MAC for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An ALJ hearing was held in early January 2015. On January 18, 2016 we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid. No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. In the event we pay any amount of this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. As of March 31, 2016 , we have recorded no liability for this claim as we do not believe that an estimate of a reasonably possible loss or range of loss can be made at this time . Insurance We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs , up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported . These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. Our health insurance has a retention limit of $ 0.9 million, our workers' compensation insurance has a retention limit of $ 0.5 million and our professional liability insurance has a retention limit of $ 0.3 million.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
SEGMENT INFORMATION	6 . Segment Information Our operations involve servicing patients through our three reportable business segments: home health , hospice and personal care . Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks . Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal ca re segment , which was established with the acquisition of Associated Home Care during the three-month period ended March 31, 2016, provides patients with assistance with the esse ntial activities of daily living . The “other” column in the following tables consist s of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration . M anagement evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attribu table to the specific segment and includes revenues and all other costs directly attributable to the specific segment . Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below (amounts in millions). For the Three-Month Period Ended March 31, 2016 Home Health Hospice Personal Care Other Total Net service revenue $ 272.7 $ 73.0 $ 3.1 $ 0.0 $ 348.8 Cost of service, excluding depreciation and amortization 160.8 38.8 2.2 0.0 201.8 General and administrative expenses 71.2 16.9 0.4 39.0 127.5 Provision for doubtful accounts 3.2 0.7 0.0 0.0 3.9 Depreciation and amortization 1.3 0.3 0.0 2.9 4.5 Operating expenses 236.5 56.7 2.6 41.9 337.7 Operating income (loss) $ 36.2 $ 16.3 $ 0.5 $ (41.9) $ 11.1 For the Three-Month Period Ended March 31, 2015 Home Health Hospice Personal Care Other Total Net service revenue $ 241.4 $ 60.2 $ 0.0 $ 0.0 $ 301.6 Cost of service, excluding depreciation and amortization 138.7 32.3 0.0 0.0 171.0 General and administrative expenses 62.8 14.4 0.0 26.8 104.0 Provision for doubtful accounts 2.6 0.4 0.0 0.0 3.0 Depreciation and amortization 1.5 0.4 0.0 4.6 6.5 Asset impairment charge 0.0 0.0 0.0 75.2 75.2 Operating expenses 205.6 47.5 0.0 106.6 359.7 Operating income (loss) $ 35.8 $ 12.7 $ 0.0 $ (106.6) $ (58.1)

SHARE REPURCHASE PROGRAM

SHARE REPURCHASE PROGRAM	3 Months Ended
	Mar. 31, 2016
Equity Abstract
SHARE REPURCHASE PROGRAM	7. STOCK REPURCHASE PROGRAM On September 9, 2015, we announced that our B oard of Directors authorized a stock repurchase program, under which we may repurchase up to $ 75 million of our outstanding common stock on or before September 6, 2016. Under the terms of the program, we may repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We may enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases, if any, will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. During the three-month period ended March 31, 2016, pursuant to this program, we repurchased 324, 141 shares of our common stock at a weighted average price of $ 37.96 per share and a total cost of approximately $ 12.3 million . The repurchased shares are classified as treasury shares.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2016
Related Party Transaction
RELATED PARTY TRANSACTION	8. RELATED PARTY TRANSACTION On November 20, 2015, we engaged KKR Capstone Consulting, LLC (“KKR Capstone”), a consulting company of operational professionals that works exclusively with portfolio companies of Kohlberg Kravis Roberts & Co. Nathaniel M. Zilkha , a member of our Board of Directors, is a member of KKR Management LLC, which is an affiliate of KKR Asset Management LLC (“KAM”), a substantial stockholder of our Company, and an affiliate of Kohlberg Kravis Roberts & Co. KKR Capstone will receive a fee of approximately $ 1.3 million in connection with providing consulting services to the Company in the ordinary course of business. Mr. Zilkha will not receive any direct compensation or direct financial benefit from the engagement of KKR Capstone. During the three-month period ended March 31, 2016, we incurred costs of approximately $ 0.6 million related to this related party engagement.

NATURE OF OPERATIONS, CONSOLI14

NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated finan cial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 , as filed with the Securities and Exchange Commission (“SEC”) on March 10, 2016 (the “Form 10-K”), which includes information and disclosures not included herein.
Use of Estimates	Use of Estimates Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Reclassifications and Comparability	Reclassifications and Comparability Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period' s presentation. In compliance with Accounting Standards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs , we have reclassified 2015 amounts related to unamortized debt issuance costs from other assets, net to long-term obligations, less current portio n.
Principles of Consolidation	Principles of Consolidation These unaudited condensed c onsolidated financial statements include the accounts of Amedisys , Inc. , and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below .
Equity Investments	Equity Investments We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50 %. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50 % or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $ 25.4 million as of March 31 , 201 6 and $ 25.7 m illion as of December 31, 201 5 . We account for investments in entities in which we have less than a 20 % ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee .
Revenue Recognition	2 . Summary of Significant Accounting Policies Revenue Recognition We earn net service revenue through our home health and hospice care center s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60 -day episode of care as episodic-based revenue. When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. Home Health Revenue Recognition Medicare Revenue Net service revenue is recorded under the Medicare prospective payment system (“PPS”) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (“LUPA”) if the number of visits was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g) changes in the base episode payments established by the Medicare Program; (h) adjustments to the base episode payments for case mix and geographic wages; and (i) recoveries of overpayments. In addition, we make adjustments to Medicare revenue if we find that we are unable to produce appropriate documentation of a face to face encounter between the patient and physician. We make adjustments to Medicare revenue to reflect differences between estimated and actual payment amounts, our discovered inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99 % on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60 -day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of March 31, 2016 and 2015 , the difference between the cash received from Medicare for a request for anticipated payment (“RAP”) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa tient accounts receivable in our condensed consolidated balance sheets for such periods. Non-Medicare Revenue Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Non-episodic b ased Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. Hospice Revenue Recognition Hospice Medicare Revenue Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continu ous home care and respite care. Routine care accounts for 98 % of our total net Medic are hospice service revenue for each of the three - month period s ended March 31, 2016 , and 2015 . We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if we estimate a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. Beginning for the cap year ending October 31, 2014, providers are required to self-report and pay their estimated cap liability by March 31 st of the following year. As of March 31, 2016, w e have settled our Medicare hospice reimbursements for all fiscal years through October 31, 20 12 . As of March 31, 201 6 and December 31, 201 5 , we have recorded $ 1.3 million and $ 1.4 million , respectively , for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October 31, 2013 through October 31, 201 6 . Hospice Non-Medicare Revenue We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv able.
Patient Accounts Receivable	Patient Accounts Receivable Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March 31, 2016 t here is one single payor, other than Medicare, that accounts for more than 10 % of our total outstanding patient receivables (approximately 11.6 %). T hus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 36 5 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the credit risk associated with our Medicare accounts , which represent 60 % and 64 % of our net patient accounts receivable at March 31, 201 6 and December 31, 2015 , respectively, is limited due to our historical collection rate of over 99 % from Medicare and the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above . During the three - month periods ended March 31, 2016 and 2015 , we recorded $ 1. 7 million and $ 1. 5 million, respectively , in estimated revenue adjustments to Medicare revenue. We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. Medicare Home Health For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60 % of our estimated payment for the initial episode at the start of care or 50 % of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (“final billed”). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted. Medicare Hospice For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient . Non-Medicare Home Health and Hospice For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. We estimate an allowance for doubtful accounts based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectability based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk .
Property Plant And Equipment	Property and Equipment Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed c om puter software for our own use . Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses. As of December 31, 2014, we had $ 75.8 million of internally developed software costs related to the development of AMS3 H ome H ealth and Hospice . Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three - month period ended March 31, 2015, we made the decision to discontinue AMS3 and recorded a non-cash asset impairment charge of $75.2 million to write-off the software costs incurred related to the development of AMS3 Home Health and Hospice . The following table summarizes the balances related to our property and equipment for the periods indicated (amounts in millions): March 31, 2016 December 31, 2015 Building and leasehold improvements 5.1 2.3 Equipment and furniture 89.2 89.6 Computer software 93.0 92.6 187.3 184.5 Less: accumulated depreciation (143.3) (141.8) $ 44.0 $ 42.7
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows: Level 1 – Quoted prices in active markets for identical assets and liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable , payroll and employee benefits and accrued expenses , we estimate the carrying amounts' approximate fair value. As of March 31, 2016, the carrying amount of our long-term debt is subject to a variable rate of interest based on current market rates, and as such, the carrying value approximates fair value .
Weighted-Average Shares Outstanding	Weighted-Average Shares Outstanding Net income ( loss ) per share attributable to Amedisys , Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calc ulate our basic and diluted net income (l oss ) attributable to Amedisys , Inc. common stock holders (amounts in thousands): For the Three-Month Periods Ended March 31 2016 2015 Weighted average number of shares outstanding - basic 32,920 32,739 Effect of dilutive securities: Stock options 82 0 Non-vested stock and stock units 506 0 Weighted average number of shares outstanding - diluted 33,508 32,739 Anti-dilutive securities 319 875
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) , which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , to defer the effective date of the standard from January 1, 2017 to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 and ASU 2015-14 will have on its consolidated financial statements and related disclosures, its transition method and the effect of the standard on its ongoing financial reporting. In April 2015, t he FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods beginning on or after December 15, 2015 . We adopted this ASU during three-month period ended March 31, 201 6 , and applied the change retrospectively for prior period balances of unamortized debt issuance costs, resulting in a $3. 4 million reduction in other assets, net and long-term obligations, less current portion, on our condensed consolidated balance sheet as of December 31, 2015. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which will require lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guidance for all periods presented. The Company is evaluating the effect that ASU 2016-02 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting . In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , which will simplify the accounting for share-based payment award transactions , including income tax consequences, classification of awards as either equity or liability and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the effect that ASU 2016-09 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting .

SUMMARY OF SIGNIFICANT ACCOUN15

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Property Plant and Equipment	The following table summarizes the balances related to our property and equipment for the periods indicated (amounts in millions): March 31, 2016 December 31, 2015 Building and leasehold improvements 5.1 2.3 Equipment and furniture 89.2 89.6 Computer software 93.0 92.6 187.3 184.5 Less: accumulated depreciation (143.3) (141.8) $ 44.0 $ 42.7
Weighted-Average Shares Outstanding	For the Three-Month Periods Ended March 31 2016 2015 Weighted average number of shares outstanding - basic 32,920 32,739 Effect of dilutive securities: Stock options 82 0 Non-vested stock and stock units 506 0 Weighted average number of shares outstanding - diluted 33,508 32,739 Anti-dilutive securities 319 875

LONG-TERM OBLIGATIONS (Tables)

LONG-TERM OBLIGATIONS (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	4. LONG-TERM OBLIGATIONS Long-term debt consisted of the following for the periods indicated (amounts in millions): March 31, 2016 December 31, 2015 $100.0 million Term Loan; principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (2.43% at March 31, 2016); due August 28, 2020 $ 98.8 $ 100.0 $200.0 million Revolving Credit Facility; interest only payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (2.44% at March 31, 2016); due August 28, 2020 15.0 0.0 Deferred debt issuance costs (3.2) (3.4) 110.6 96.6 Current portion of long-term obligations (20.0) (5.0) Total $ 90.6 $ 91.6

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Operating Income of Reportable Segments	For the Three-Month Period Ended March 31, 2016 Home Health Hospice Personal Care Other Total Net service revenue $ 272.7 $ 73.0 $ 3.1 $ 0.0 $ 348.8 Cost of service, excluding depreciation and amortization 160.8 38.8 2.2 0.0 201.8 General and administrative expenses 71.2 16.9 0.4 39.0 127.5 Provision for doubtful accounts 3.2 0.7 0.0 0.0 3.9 Depreciation and amortization 1.3 0.3 0.0 2.9 4.5 Operating expenses 236.5 56.7 2.6 41.9 337.7 Operating income (loss) $ 36.2 $ 16.3 $ 0.5 $ (41.9) $ 11.1 For the Three-Month Period Ended March 31, 2015 Home Health Hospice Personal Care Other Total Net service revenue $ 241.4 $ 60.2 $ 0.0 $ 0.0 $ 301.6 Cost of service, excluding depreciation and amortization 138.7 32.3 0.0 0.0 171.0 General and administrative expenses 62.8 14.4 0.0 26.8 104.0 Provision for doubtful accounts 2.6 0.4 0.0 0.0 3.0 Depreciation and amortization 1.5 0.4 0.0 4.6 6.5 Asset impairment charge 0.0 0.0 0.0 75.2 75.2 Operating expenses 205.6 47.5 0.0 106.6 359.7 Operating income (loss) $ 35.8 $ 12.7 $ 0.0 $ (106.6) $ (58.1)

Nature of Operations Consolidat

Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)Agencies	Mar. 31, 2015	Dec. 31, 2015USD ($)
Organization And Nature Of Operations [Line Items]
Percent Of Net Services Revenue Provided By Medicare	79.00%	81.00%
Number Of States With Facilities	34
Minimum percent ownership for controlling interest percent	50.00%
Equity Method Investment Aggregate Cost | $	$ 25.4		$ 25.7
Maximum Percent Ownership For Equity Method Percent	50.00%
Maximum Percent Ownership For Cost Method Percent	20.00%
Home Health [Member]
Organization And Nature Of Operations [Line Items]
Operating Care Centers	329
Hospice [Member]
Organization And Nature Of Operations [Line Items]
Operating Care Centers	79
Personal Care [Member]
Organization And Nature Of Operations [Line Items]
Operating Care Centers	9

Summary of Significant Accoun19

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016USD ($)DNumber_of_Visits	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Episode of care as episodic-based revenue, days | D	60
Percentage of total reimbursement of outlier payment	10.00%
Low utilization payment adjustment, maximum number of visits | Number_of_Visits	5
First threshold of therapy services required, visits | Number_of_Visits	6
Second threshold of services required, visits | Number_of_Visits	14
Third threshold of therapy services required, visits | Number_of_Visits	20
Historical collection rate from Medicare	99.00%
Episodes in progress that begin during reporting period, days | D	60
Hospice Medicare revenue rate accounted for routine care	98.00%	98.00%
Percentage of patient receivables outstanding	10.00%
Minimum days for accounts receivable outstanding to be fully reserved | D	365
Portion of accounts receivable derived from Medicare	60.00%		64.00%
Revenue adjustment to Medicare revenue	$ 1,700	$ 1,500
Rate of request for anticipated payment submitted for the initial episode of care	60.00%
Rate of request for anticipated payment submitted for subsequent episodes of care	50.00%
Maximum days to submit final bill from the start of episode | D	120
Maximum days to submit final bill from the date the request for anticipated payment was paid | D	60
Percentage Of Patient Receivables Outstanding Over Ten Percent	11.60%
Asset Impairment Charges	$ 0	75,193
Property Plant And Equipment [Line Items]
Internally developed computer software				$ 75,800
Unamortized debt issuance costs	(3,200)		$ (3,400)
Home Health [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Asset Impairment Charges	0	0
Hospice [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Asset Impairment Charges	0	$ 0
Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Estimated amounts due back to Medicare	$ 1,300		$ 1,400

Schedule of Balances Related to

Schedule of Balances Related to Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Building and leasehold improvements	$ 5,100	$ 2,300
Equipment and furniture	89,200	89,600
Computer software	93,000	92,600
Property and Equipment, Gross	187,300	184,500
Less accumulated depreciation	(143,277)	(141,793)
Property and equipment, net	$ 43,963	$ 42,695

Schedule of Weighted Average Sh

Schedule of Weighted Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accounting Policies [Abstract]
Weighted average number of shares outstanding - basic	32,920	32,739
Stock options	82	0
Non-vested stock and stock units	506	0
Weighted average number of shares outstanding - diluted	33,508	32,739
Anti-dilutive securities	319	875

Acquisitions (Detail)

Acquisitions (Detail) - Massachusetts [Member] - Personal Care [Member] $ in Millions	2 Months Ended
	Mar. 01, 2016USD ($)Agencies
Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]
Acquisition, total purchase price	$ 27.7
Acquisition, number of care centers acquired | Agencies	9
Acquisition, recorded other assets and liabilities	$ 4.2
Escrow depost for indemnification purposes and working capital price adjustments	0.5
Additions	$ 23.5

Long Term Debt (Detail)

Long Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt including current portion	$ 110,600	$ 96,600
Current portion of long-term obligations	(20,000)	(5,000)
Unamortized Debt Issuance Expense	(3,200)	(3,400)
Total	90,600	91,600
One Hundred Million Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt including current portion	98,800	100,000
Two Hundred Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt including current portion	$ 15,000	$ 0

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Total leverage ratio	1
Fixed charge coverage ratio	3.8
Long-term debt including current portion	$ 110.6	$ 96.6
Unamortized Debt Issuance Expense	$ (3.2)	(3.4)
One Hundred Million Term Loan [Member]
Debt Instrument [Line Items]
Weighted-average interest rate for five year Term Loan	2.40%
Principal amount	$ 100
Maturity date	Aug. 28, 2020
Long-term debt including current portion	$ 98.8	100
Two Hundred Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Weighted-average interest rate for five year Term Loan	2.70%
Principal amount	$ 200
Availability under the revolving credit facility	160.3
Outstanding letters of credit	$ 24.7
Maturity date	Aug. 28, 2020
Long-term debt including current portion	$ 15	$ 0

Long Term Debt (Parenthetical)

Long Term Debt (Parenthetical) (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
One Hundred Million Term Loan [Member]
Debt Instrument [Line Items]
Principal amount	$ 100
Eurodollar Rate plus the applicable percentage	2.43%
Maturity date	Aug. 28, 2020
Two Hundred Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Principal amount	$ 200
Eurodollar Rate plus the applicable percentage	2.44%
Maturity date	Aug. 28, 2020

Commitments and Contingencies (

Commitments and Contingencies (Detail)

Mar. 02, 2015ComputersResidents

Jan. 18, 2016USD ($)Claims

Apr. 30, 2014Agencies

Jan. 31, 2014Claims

Mar. 09, 2011USD ($)Claims

Mar. 31, 2016USD ($)Agencies

Jun. 10, 2015USD ($)

May. 21, 2015

Jun. 06, 2011Beneficiary

Jul. 25, 2012Employee

Sep. 13, 2012Employee

Nov. 03, 2015

Nov. 10, 2009Claims

Mar. 31, 2010Beneficiary

Dec. 31, 2015USD ($)

Sep. 30, 2015USD ($)

Commitments and Contingencies Disclosure [Line Items]

Health insurance retention limit

$ 900,000

Workers' compensation insurance retention limit

500,000

Professional liability insurance retention limit

$ 300,000

Corporate Integrity Agreement Term

5 years

Number Of States With Facilities | Agencies

34

Wage and Hour Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Loss Contingency, Settlement Agreement, Consideration

$ 8,000,000

Loss Contingency Accrual, at Carrying Value

$ 5,300,000

$ 8,000,000

Wage and Hour Litigation [Member] | Illinois [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of former employees who filled a putative collective and class action complaint | Employee

1

Loss Contingency Accrual

$ 800,000

Wage and Hour Litigation [Member] | Connecticut [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of former employees who filled a putative collective and class action complaint | Employee

3

OIG Self-Disclosure [Member]

Commitments and Contingencies Disclosure [Line Items]

Loss Contingency Accrual

$ 4,700,000

Computer Inventory And Data Security Reporting [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of Missing Computers and Laptops | Computers

142

Threshold of Individuals in Data Breach | Residents

500

Computer Inventory And Data Security Reporting [Member] | Minimum [Member]

Commitments and Contingencies Disclosure [Line Items]

Year of Departure

2,011

Computer Inventory And Data Security Reporting [Member] | Maximum [Member]

Commitments and Contingencies Disclosure [Line Items]

Year of Departure

2,014

Home Health [Member] | Ohio [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of claims submitted by subsidiary | Claims

137

Home Health [Member] | Extrapolated [Member] | Ohio [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of claims submitted by subsidiary | Claims

114

Recovery amount of the overpayment made to the subsidiary

$ 5,600,000

Home Health [Member] | Unfavorable [Member] | Ohio [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of claims submitted by subsidiary | Claims

28

Home Health [Member] | Favorable In Full [Member] | Ohio [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of claims submitted by subsidiary | Claims

76

Number of claims appealed | Claims

74

Home Health [Member] | Favorable In Part [Member] | Ohio [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of claims submitted by subsidiary | Claims

10

Number of claims appealed | Claims

8

Home Health [Member] | Frontier Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Number Of Care Centers Sold | Agencies

5

Hospice [Member] | South Carolina [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of beneficiaries | Beneficiary

30

Hospice [Member] | Extrapolated [Member] | South Carolina [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of beneficiaries | Beneficiary

16

Hospice [Member] | Unfavorable [Member] | South Carolina [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of claims submitted by subsidiary | Claims

9

Recovery amount of the overpayment made to the subsidiary

$ 3,700,000

Recovery Amount Of Over Payment Made To Subsidiary Including Interest

$ 5,600,000

Hospice [Member] | Frontier Litigation [Member]

Commitments and Contingencies Disclosure [Line Items]

Number Of Care Centers Sold | Agencies

4

Hospice [Member] | U.S. Department of Justice [Member] | Massachusetts [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patients

53

Hospice [Member] | U.S. Department of Justice [Member] | West Virginia [Member]

Commitments and Contingencies Disclosure [Line Items]

Number of patients

66

Segment Information - Additiona

Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016Segments
Segment Reporting [Abstract]
Number of reportable business segments	3

Operating Income of Reportable

Operating Income of Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Net service revenue	$ 348,817	$ 301,572
Cost of service, excluding depreciation and amortization	201,837	170,961
General and administrative expenses	127,500	104,000
Provision for doubtful accounts	3,940	2,976
Depreciation and amortization	4,473	6,537
Asset impairment charge	0	75,193
Operating expenses	337,754	359,676
Operating income (loss)	11,063	(58,104)
Home Health [Member]
Segment Reporting Information [Line Items]
Net service revenue	272,700	241,400
Cost of service, excluding depreciation and amortization	160,800	138,700
General and administrative expenses	71,200	62,800
Provision for doubtful accounts	3,200	2,600
Depreciation and amortization	1,300	1,500
Asset impairment charge	0	0
Operating expenses	236,500	205,600
Operating income (loss)	36,200	35,800
Hospice [Member]
Segment Reporting Information [Line Items]
Net service revenue	73,000	60,200
Cost of service, excluding depreciation and amortization	38,800	32,300
General and administrative expenses	16,900	14,400
Provision for doubtful accounts	700	400
Depreciation and amortization	300	400
Asset impairment charge	0	0
Operating expenses	56,700	47,500
Operating income (loss)	16,300	12,700
Personal Care [Member]
Segment Reporting Information [Line Items]
Net service revenue	3,100	0
Cost of service, excluding depreciation and amortization	2,200	0
General and administrative expenses	400	0
Provision for doubtful accounts	0	0
Depreciation and amortization	0	0
Asset impairment charge	0	0
Operating expenses	2,600	0
Operating income (loss)	500	0
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net service revenue	0	0
Cost of service, excluding depreciation and amortization	0	0
General and administrative expenses	39,000	26,800
Provision for doubtful accounts	0	0
Depreciation and amortization	2,900	4,600
Asset impairment charge	0	75,200
Operating expenses	41,900	106,600
Operating income (loss)	$ (41,900)	$ (106,600)

Share Repurchase Program (Detai

Share Repurchase Program (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Sep. 09, 2015
Equity Abstract
Share Repurchase Program authorized amount			$ 75,000
Treasury Stock Shares Acquired	324,141
Treasury Stock Acquired Average Cost Per Share	$ 37.96
Purchase of company stock	$ 12,315	$ 0

Related Party Transaction (Deta

Related Party Transaction (Detail) - USD ($) $ in Millions	3 Months Ended	11 Months Ended
	Mar. 31, 2016	Nov. 20, 2015
Related Party Transaction
Related party transaction expenses	$ 0.6
Related party transaction amount		$ 1.3